Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Documenti analoghi

• Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
  di: Raschi, Emanuel, et al.
  Pubblicazione: (2020)
• Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
  di: Gatti, Milo, et al.
  Pubblicazione: (2021)
• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  di: Raschi, Emanuel, et al.
  Pubblicazione: (2021)
• Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
  di: Gatti, Milo, et al.
  Pubblicazione: (2021)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  di: Raschi, Emanuel, et al.
  Pubblicazione: (2019)